Document is current
Any future updates will be listed below
-
Authors
Nerviani, Alessandra http://orcid.org/0000-0003-4064-4014
Boutet, Marie-Astrid
Ghirardi, Giulia Maria http://orcid.org/0000-0002-4176-2031
Goldmann, Katriona
Sciacca, Elisabetta http://orcid.org/0000-0001-7525-1558
Rivellese, Felice http://orcid.org/0000-0002-6759-7521
Pontarini, Elena http://orcid.org/0000-0003-0439-0344
Prediletto, Edoardo http://orcid.org/0000-0001-6830-0614
Abatecola, Federico http://orcid.org/0009-0008-2409-1396
Caliste, Mattia
Pagani, Sara
Mauro, Daniele
Bellan, Mattia
Cubuk, Cankut
Lau, Rachel http://orcid.org/0000-0002-8330-8048
Church, Sarah E. http://orcid.org/0000-0002-7194-4282
Hudson, Briana M.
Humby, Frances
Bombardieri, Michele
Lewis, Myles J. http://orcid.org/0000-0001-9365-5345
Pitzalis, Costantino http://orcid.org/0000-0003-1326-5051
-
Funding
Funding for this research was provided by:
RCUK | Medical Research Council (G0800648)
DH | NIHR | Efficacy and Mechanism Evaluation Programme (11/100/76)
DH | National Institute for Health Research (131575, TRF-2018-11-ST2-002)
RCUK | MRC | Medical Research Foundation (MR/V012509/1)
Versus Arthritis [Experimental Arthritis Treatment Centre, grant number 20022]
Versus Arthritis, grant number 21890
Fondation pour la Recherche Médicale (ARF202004011786)
Inserm “ATIP-Avenir” program
- License Information
-
More Information
Article History
Received: 8 March 2023
Accepted: 27 February 2024
First Online: 16 March 2024
Competing interests
: S.E.C. and B.M.H. are Nanostring employees and stockholders. C.P. and M.J.L. are inventors on a patent application (no. GB 2100821.4), submitted by Queen Mary University of London, that covers methods used to select treatments in R.A. All other authors declare no competing interests.
